SCHEMBL6484565

SCHEMBL6484565

Cc1c(=O)c(Cc2ccc(F)c(F)c2)cn2cc(C(=O)O)sc12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.35
P2RY14 Q15391 1/20 0.33
TRPC5 Q9UL62 1/20 0.33
KDM5A P29375 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
LMNA P02545 2/20 0.32
CHRM4 P08173 1/20 0.32
TRPA1 O75762 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
SCD O00767 1/20 0.31
TP53 P04637 2/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476858 0.85 TRPA1 (0.49) CHRM4TRPA1S1PR3MAPTALDH1A1
SCHEMBL6814148 0.84 LOXL2 (0.40) KDM5AKDM5BTRPA1
SCHEMBL6814142 0.84 KDM5A (0.35) P2RY14KDM5AKDM5BTRPA1SCD
SCHEMBL6476888 0.79 RXRA (0.35) RXRAP2RY14KDM5AKDM5BTP53
SCHEMBL6485426 0.78 P2RY14 (0.36) RXRAP2RY14KDM5AKDM5BCHRM4
SCHEMBL6484250 0.78 FFAR1 (0.33)
SCHEMBL6814145 0.77 TRPA1 (0.52) CHRM4TRPA1SCDMAPTMAPK1
SCHEMBL6289346 0.73 PKM (0.39) RXRAP2RY14KDM5AKDM5BLMNA
SCHEMBL6289386 0.72 MAPK14 (0.36) RXRAP2RY14TRPC5KDM5AKDM5B
SCHEMBL6233513 0.70 TRPA1 (0.58) TRPA1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 RXRA 1370/4885P2RY14 3000/4885TRPC5 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.